Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Walling

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
International Journal of Clinical Pharmacology and Therapeutics|April 18, 2015
Effect of pomaglumetad methionil on the QT interval in subjects with schizophreniaWei Zhang, Malcolm I Mitchell, Mary Pat Knadler, et al.
Journal of Clinical Psychopharmacology|June 21, 2016
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Journal of Clinical Psychopharmacology|September 4, 2010
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizersCarla M Canuso, Nina Schooler, Jennifer Carothers, et al.
Schizophrenia Bulletin|February 25, 2022
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaMichael Davidson, Jay Saoud, Corinne Staner, et al.
Innovations in Clinical Neuroscience|July 15, 2016
Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders, David Daniel, Amir Kalali, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 14, 2014
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyW Wolfgang Fleischhacker, Raymond Sanchez, Pamela P Perry, et al.
Schizophrenia Bulletin|June 14, 2015
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaDavid Walling, Stephen R Marder, John Kane, et al.
The American Journal of Psychiatry|February 3, 2011
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophreniaMichael F Green, Nina R Schooler, Robert S Kern, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
International Journal of Clinical Pharmacology and Therapeutics|April 18, 2015
Effect of pomaglumetad methionil on the QT interval in subjects with schizophreniaWei Zhang, Malcolm I Mitchell, Mary Pat Knadler, et al.
Journal of Clinical Psychopharmacology|June 21, 2016
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Journal of Clinical Psychopharmacology|September 4, 2010
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizersCarla M Canuso, Nina Schooler, Jennifer Carothers, et al.
Schizophrenia Bulletin|February 25, 2022
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaMichael Davidson, Jay Saoud, Corinne Staner, et al.
Innovations in Clinical Neuroscience|July 15, 2016
Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders, David Daniel, Amir Kalali, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 14, 2014
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyW Wolfgang Fleischhacker, Raymond Sanchez, Pamela P Perry, et al.
Schizophrenia Bulletin|June 14, 2015
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaDavid Walling, Stephen R Marder, John Kane, et al.
The American Journal of Psychiatry|February 3, 2011
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophreniaMichael F Green, Nina R Schooler, Robert S Kern, et al.
Pageof 2